DENVER , April 9, 2012 /PRNewswire/ -- MusclePharm Corporation (OTCBB: MSLP), a nutritional supplement company focusing on all categories of an active lifestyle, today announced that the peer-reviewed journal, Nutrition and Metabolism, published a scientific paper showing positive results on the Phase 1 clinical trial of the company's pre-workout supplement, Assault™.
Conducted at the United States Sports Academy (USSA) (www.ussa.edu), the study suggests that ingesting Assault™ 20 minutes prior to exercise can improve agility, quickness and lower-body muscular strength in both strength and/or endurance-trained young adult males. Moreover, the study showed that Assault™ can improve energy, focus and alertness, and delay fatigue.
The purpose of the USSA study was to determine the effects of Assault™ on upper and lower body muscular endurance, aerobic and anaerobic capacity, and choice reaction time in recreationally-trained males. Subjective feelings of energy, fatigue, alertness and focus were measured to examine associations between psychological factors and human performance.
Researchers concluded that ingesting Assault™ before exercise significantly improved agility choice reaction performance and lower body muscular endurance, while increasing perceived energy and reducing subjective fatigue.
"Our findings suggest that Assault™ can provide athletes with an overall better workout experience by prolonging exercise performance, reducing fatigue and increasing energy-levels," said Jordan R. Moon , Ph.D., lead researcher of the clinical trial and USSA's Head of the Department of Sports Fitness and Health . "The athlete-subjects who consumed Assault lifted more weight, were faster in every reaction test and were motivated to continue to exercise with higher levels of focus and alertness than those on placebo."
"MusclePharm is one of only a few companies to support its products with clinical studies and scientific research," said Brad Pyatt , chief executive officer of MusclePharm. "Assault is the only pre-workout product on the market that is certified by both NSF International and Informed Choice as free of banned substances. These are some of the reasons why so many athletes and professional organizations partner with us, and why we believe MusclePharm is the future in the sports nutrition industry."
The abstract is entitled "Ingesting a pre-workout supplement containing caffeine, B-vitamins, amino acids, creatine, and beta-alanine before exercise delays fatigue while improving reaction time and muscular endurance" and can be downloaded at www.nutritionandmetabolism.com/content/9/1/28/abstract.
ABOUT MUSCLEPHARM CORPORATION
MusclePharm is a healthy life-style company that develops and manufactures a full line of NSF International and Informed Choice approved nutritional supplements that are free of banned substances. Based on years of research at the MusclePharm Sports Science Center , the products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than one hundred elite professional athletes from various professional sports leagues including the National Football League , Mixed Martial Arts and Major League Baseball . The company's products address all categories of an active lifestyle, including muscle building, weight loss and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in more than 120 countries and available in over 10,000 U.S. retail outlets, including Dick's Sporting Goods , GNC , Vitamin Shoppe , Vitamin World and Walmart. MusclePharm products also are sold through more than 100 online stores, including bodybuilding.com, Amazon.com and Vitacost.com . For more information, please visit www.musclepharm.com.
FORWARD LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements, including, but not limited to, product claims for the pre-work supplement, Assault, relate to future events or to future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Undue reliance should not be placed on forward-looking statements, since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. MusclePharm assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information, contact: MusclePharm Cory Gregory , President 303-396-6100
Or
PondelWilkinson Inc. Roger Pondel / Robert Jaffe 310-278-5980
SOURCE MusclePharm Corporation
AI
News 
Market Data 
Discover 
